Consumer healthcare and weak euro spare Sanofi-Aventis blushes
This article was originally published in Scrip
Sanofi-Aventis' consumer healthcare and generics businesses helped spare any blushes as the French pharma giant reported its annual results for 2010. Overall, sales declined by just under 1% to €30.4 billion with more than €2 billion of sales, notably of Lovenox (enoxaparin) in the US, were lost through generic competition. The weak euro was also a big contributor to shoring up Sanofi-Aventis' financials.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.